Company Description

Climb Bio, formerly Eliem Therapeutics, s a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. Their lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.